New combo attack on recurrent rectal cancer shows promise in early trial
NCT ID NCT07183865
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a powerful mix of radiation, chemotherapy, immunotherapy, and targeted therapy in 44 patients with locally recurrent rectal cancer that has not responded to prior treatment. The goal is to shrink tumors and enable surgery. Researchers are measuring how many patients see their tumors shrink or disappear, and how long that effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Irinotecan hydrochloride liposome, 5-FU, leucovorin, PD-1 antibody (SG001), and targeted therapy (C225 or bevacizumab)
- What this could lead to
- If successful, this could offer a new treatment option for patients with recurrent rectal cancer that has not responded to standard chemotherapy, potentially improving tumor shrinkage and surgical outcomes.
- What could go wrong
- This is an early-phase, single-arm trial with only 44 participants, so results may not apply to all patients. The combination therapy has multiple drugs, increasing the risk of side effects, and it is not yet compared to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.